GlobalData on MSN3mon
Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitisArcutis Biotherapeutics' subsidiary, Arcutis Canada, has received Health Canada's approval for ZORYVE (roflumilast) topical ...
Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on January 13.Invest with Confidence: ...
This aligns with the broader analyst consensus, as revealed by InvestingPro data, with price targets ranging from $12 to $29. According to the firm, Arcutis' Zoryve product line, which includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback